Diphenhydramine

ID: diphenhydramine

Aliases: Benadryl, DPH, diphenhydramine hydrochloride

Type: compound

Route/form: oral/topical/injectable depending product; sleep-aid discussion is oral OTC context

Status: otc_or_prescription_by_product

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, review/regulatory

Source types: evidence_report, human_association_and_preclinical, label, systematic_review

Linked sources: 7

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• H1 histamine receptor antagonism
• anticholinergic activity
• sedation

Optimization domains

• allergy
• sleep
• insomnia
• anticholinergic
• dementia
• sedation

Research basis

• Diphenhydramine has labelled antihistamine use and predictable sedating H1/anticholinergic pharmacology, explaining its presence in OTC sleep stacks.
• Its repository value is mostly as a risk/comparator entry: it is common, familiar, and often underestimated.
• Guideline and review sources make the skepticism legible rather than preference-based.

Limits, risks, and missing evidence

• AASM guidance suggests not using diphenhydramine for adult sleep-onset or sleep-maintenance insomnia.
• Long-term cumulative exposure to strong anticholinergic drugs has been associated with higher dementia risk in observational older-adult cohorts; this is a class-level risk signal rather than diphenhydramine-specific causal proof.
• Anticholinergic burden, tolerance to sedation, next-day impairment, confusion/falls in susceptible users, urinary retention, and overdose toxicity are major drawbacks.
• Combining with other anticholinergic/sedating drugs can create far more risk than benefit.

Risk flags

• approved otc drug
• sedating
• anticholinergic
• cumulative anticholinergic burden
• dementia association observational
• older adult high risk
• next day impairment
• stack interactions

Linked papers, labels, and reviews

1. DailyMed label: diphenhydramine hydrochloride OTC allergy-relief tablet
   label / dailymed_diphenhydramine_otc_label
   OTC diphenhydramine label warning about duplicate diphenhydramine products and marked drowsiness.
2. Over-the-Counter Agents for the Treatment of Occasional Disturbed Sleep or Transient Insomnia
   systematic_review / pubmed_otc_sleep_aids_review_2016
   Systematic review of OTC sleep-aid efficacy and safety; diphenhydramine evidence was limited and not robust.
3. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults
   evidence_report / pubmed_aasm_insomnia_guideline_2017
   American Academy of Sleep Medicine pharmacologic insomnia guideline; includes recommendations against trazodone and diphenhydramine for chronic adult insomnia.
4. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study
   human_association_and_preclinical / pubmed_anticholinergic_dementia_gray_2015
   Older-adult prospective cohort; higher 10-year cumulative strong anticholinergic exposure was associated with incident dementia, with first-generation antihistamines among common exposure classes.
5. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study
   human_association_and_preclinical / pubmed_anticholinergic_dementia_coupland_2019
   Large nested case-control study; supports cumulative anticholinergic burden as a dementia-risk signal while requiring class-specific and confounding-aware interpretation.
6. Anticholinergic burden for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome
   systematic_review / cochrane_anticholinergic_burden_dementia_2021
   Cochrane prognostic-factor review on anticholinergic burden and future cognitive decline or dementia; useful for uncertainty and evidence-quality framing.
7. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults
   evidence_report / pubmed_ags_beers_criteria_2023
   Geriatric prescribing criteria covering strongly anticholinergic drugs, including first-generation antihistamines and selected antidepressants; useful for older-adult delirium, falls, cumulative anticholinergic burden, and dementia-risk framing.